Clinical trial
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma
NCT06389799 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma
- Lead sponsor
- Lund University Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 20, 2024
- Completion date
- December 31, 2028
- Enrollment
- 33 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
dedifferentiated liposarcoma